State Street’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-140,898
| Closed | -$823K | – | 4872 |
|
|
2022
Q4 | $823K | Buy |
140,898
+20,300
| +17% | +$107K | ﹤0.01% | 3606 |
|
|
2022
Q3 | $808K | Buy |
120,598
+18,700
| +18% | +$113K | ﹤0.01% | 3645 |
|
|
2022
Q2 | $429K | Buy |
101,898
+26,100
| +34% | +$103K | ﹤0.01% | 3888 |
|
|
2022
Q1 | $255K | Buy |
75,798
+5,058
| +7% | +$16K | ﹤0.01% | 4304 |
|
|
2021
Q4 | $223K | Hold |
70,740
| – | – | ﹤0.01% | 4306 |
|
|
2021
Q3 | $231K | Sell |
70,740
-4,300
| -6% | -$15.1K | ﹤0.01% | 4303 |
|
|
2021
Q2 | $317K | Sell |
75,040
-394,415
| -84% | -$1.67M | ﹤0.01% | 4028 |
|
|
2021
Q1 | $2.34M | Sell |
469,455
-23,133
| -5% | -$187K | ﹤0.01% | 3373 |
|
|
2020
Q4 | $6.23M | Sell |
492,588
-1,866
| -0.4% | -$21.3K | ﹤0.01% | 2857 |
|
|
2020
Q3 | $4.86M | Buy |
494,454
+9,745
| +2% | +$96K | ﹤0.01% | 2806 |
|
|
2020
Q2 | $4.82M | Buy |
484,709
+15,689
| +3% | +$150K | ﹤0.01% | 2776 |
|
|
2020
Q1 | $4.15M | Buy |
469,020
+60,764
| +15% | +$599K | ﹤0.01% | 2725 |
|
|
2019
Q4 | $3.77M | Buy |
408,256
+4,531
| +1% | +$32.1K | ﹤0.01% | 2980 |
|
|
2019
Q3 | $2.37M | Buy |
403,725
+26,393
| +7% | +$280K | ﹤0.01% | 3154 |
|
|
2019
Q2 | $4.53M | Sell |
377,332
-11,959
| -3% | -$129K | ﹤0.01% | 2885 |
|
|
2019
Q1 | $4.7M | Sell |
389,291
-55,219
| -12% | -$814K | ﹤0.01% | 2775 |
|
|
2018
Q4 | $5.58M | Sell |
444,510
-1,283
| -0.3% | -$17.7K | ﹤0.01% | 2664 |
|
|
2018
Q3 | $6.61M | Buy |
445,793
+30,475
| +7% | +$479K | ﹤0.01% | 2727 |
|
|
2018
Q2 | $6.99M | Buy |
415,318
+33,406
| +9% | +$649K | ﹤0.01% | 2698 |
|
|
2018
Q1 | $8.74M | Buy |
381,912
+90,260
| +31% | +$2.01M | ﹤0.01% | 2526 |
|
|
2017
Q4 | $7.55M | Sell |
291,652
-23,190
| -7% | -$467K | ﹤0.01% | 2592 |
|
|
2017
Q3 | $4.64M | Buy |
314,842
+14,749
| +5% | +$214K | ﹤0.01% | 2836 |
|
|
2017
Q2 | $4.19M | Buy |
300,093
+26,024
| +9% | +$384K | ﹤0.01% | 2824 |
|
|
2017
Q1 | $4.67M | Sell |
274,069
-75,436
| -22% | -$905K | ﹤0.01% | 2730 |
|
|
2016
Q4 | $3.59M | Buy |
349,505
+12,690
| +4% | +$116K | ﹤0.01% | 2859 |
|
|
2016
Q3 | $3.41M | Buy |
336,815
+7,046
| +2% | +$77K | ﹤0.01% | 2764 |
|
|
2016
Q2 | $3.71M | Sell |
329,769
-1,836
| -0.6% | -$23.4K | ﹤0.01% | 2775 |
|
|
2016
Q1 | $4.53M | Buy |
331,605
+107,046
| +48% | +$1.54M | ﹤0.01% | 2603 |
|
|
2015
Q4 | $4.26M | Buy |
224,559
+31,745
| +16% | +$690K | ﹤0.01% | 2617 |
|
|
2015
Q3 | $3.62M | Buy |
192,814
+69,108
| +56% | +$1.17M | ﹤0.01% | 2679 |
|
|
2015
Q2 | $1.84M | Buy |
123,706
+112,506
| +1,005% | +$1.71M | ﹤0.01% | 3083 |
|
|
2015
Q1 | $169K | Buy |
+11,200
| New | +$156K | ﹤0.01% | 3504 |
|
|
2014
Q2 | – | Sell |
-43,859
| Closed | -$590K | – | 3685 |
|
|
2014
Q1 | $590K | Buy |
+43,859
| New | +$619K | ﹤0.01% | 3340 |
|
State Street's CNCE Position: Q1 2023 in Review
State Street sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 140,898 shares — an estimated $823K sold.
State Street first reported a position in CNCE in Q1 2014 and held it in 33 quarters. The position peaked at $8.74M in Q1 2018. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- State Street reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- State Street sold 140,898 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $823K.
- State Street first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 33 quarters.
- State Street's Concert Pharmaceuticals, Inc. position peaked at $8.74M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on State Street's 13F filing for Q1 2023, filed 15 May 2023.